The muddled state of patent eligibility law has direct and significant negative consequences for U.S. R&D investment, and for innovation in key fields of medical, economic, and strategic importance to the United States and its citizens. Uncertainty reduces R&D investment, as has been well-documented, and reliable patent protection mitigates uncertainty and generates increased R&D investment. As we explained in Part I of this series, the experts overwhelmingly agree on these points.
Recent Posts
- In the Final Round of Harris vs. Trump: Who is Better for IP Rights?
- Cellspin Attempt at Recusal in Case Against Fitbit Falls Flat at CAFC
- Other Barks & Bites for Friday, November 1: USCO Grants Right to Repair Copyright Exemption to Restaurants; EU Hits Teva with $503 Million Fine for Misusing Patent System; and Former USPTO Director Andrei Iancu Endorses Trump
- CAFC Affirms Several PTAB Findings that Centripetal’s Network Security Patent Claims are Obvious
- Perlmutter Gets Pressure from Congress to Release AI Reports